With no initial funding, CDR Life leveraged its team's expertise to develop and out-license an ophthalmology program. This non-dilutive deal with Boehringer Ingelheim provided the capital and validation needed to fund its primary mission in oncology and later secure a Series A round.

The company's origin was entirely serendipitous. Co-founder Steffen-Sebastian Bolz was helping a friend raise funds for a project. Once the money was secured, the original team disassembled. Instead of letting the opportunity die, Bolz's team decided to pursue the now-funded idea themselves, demonstrating how agility can turn unexpected failures into new ventures.

Airway Therapeutics defied convention by raising nearly $100 million from family offices and high-net-worth individuals, not traditional VCs. This strategy funded the company through a pivotal Phase 2B/3 trial, proving that alternative capital sources can successfully fuel late-stage biotech development before institutional rounds.

To maintain product focus and avoid the 'raising money game,' the founders of Cues established a separate trading company. They used the profits from this successful venture to self-fund their AI startup, enabling them to build patiently without being beholden to VC timelines or expectations.

Terry Rosen saw an opportunity as big pharma culturally shifted from deep R&D towards an asset-management model. He founded Arcus to fill this gap, building a company focused on the small molecule drug discovery expertise that the industry was starting to abandon, creating a counter-cyclical advantage.

Atai's leadership change from a business-focused founder to a CSO-turned-CEO was a strategic move reflecting its evolution. The company shifted from an asset-gathering model to a traditional biotech focused on advancing its internal pipeline. The co-CEO role was a planned intermediate step to ensure a smooth, controlled transition.

The company's lead molecule was initially invented to treat CNS diseases like Alzheimer's. A pivot occurred when a postdoc with an interest in oncology tested the compounds against refractory tumors, uncovering their true potential and leading to the company's formation around a new indication.

Unlike in tech where an IPO is often a liquidity event for early investors, a biotech IPO is an "entrance." It functions as a financing round to bring in public market capital needed for expensive late-stage trials. The true exit for investors is typically a future acquisition.

A massive, multi-trillion dollar wealth transfer is making family offices more institutionalized and eager to diversify into alternative investments like life sciences. Luba Greenwood points to this as a significant, often overlooked fundraising channel for biotech companies seeking direct investment.